(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1587475

米国の臨床試験市場規模、シェア、動向分析レポート：フェーズ別、適応症別、試験デザイン別、スポンサー別、サービス別、セグメント予測、2025年～2030年

U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Indication by Study Design, By Sponsor, By Service, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.81円
米国の臨床試験市場規模、シェア、動向分析レポート：フェーズ別、適応症別、試験デザイン別、スポンサー別、サービス別、セグメント予測、2025年～2030年
出版日: 2024年10月24日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の臨床試験市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の臨床試験の市場規模は2030年までに577億9,000万米ドルに達すると推定され、2025年から2030年までのCAGRは6.30％を記録します。

米国では慢性疾患の有病率が高まり、臨床試験の需要が高まっていることが市場の成長を後押ししています。

がんと診断される人の数は、今後8年間で数倍に増加すると予想されています。腫瘍学分野の調査により生存者はかなり増加したが、がん患者数は世界中で増加すると予想されます。膵臓がんは予後不良で、生存期間はわずか1～3年です。毎日約13人が消化管間質腫瘍と診断されています。米国では毎年60,000例以上の腎細胞がんが新たに診断されており、がんの有病率の増加と様々ながんに対する効果的な治療法の必要性を表しています。研究開発への投資は、米国における疾患の流行により増加し、業界の成長を後押しすると予想されます。

COVID-19の大流行により、新たな研究プロジェクトは中止され、他の疾患への資源再配分が行われています。国境が封鎖された結果、臨床試験サンプルのサプライチェーンも中断しています。したがって、この市場は混乱しています。しかし、COVID-19の対応は、臨床試験の実施を一変させる新たな市場開拓をもたらしました。分散型/バーチャル臨床試験はそのような手法の一つです。バーチャル臨床試験は、現在のCOVID-19シナリオにおいて非常に重要な役割を担っています。バーチャル訪問と遠隔患者モニタリングの結果、参加者はリスクを最小限に抑える選択肢と安心感を得ることができます。モニタリングガジェット、ソフトウェアツール、携帯電話により、参加者は自宅から実験を完了することができます。

米国臨床試験市場レポート・ハイライト

  • 2024年、第III相試験が最も高い売上シェアを占めました。これらの臨床試験は、300～3000人の参加者を対象とし、期間も長いため、より重要です。したがって、最も費用がかかるフェーズです。
  • 試験デザイン別では、介入デザインセグメントが米国市場を独占し、2024年に最大の売上シェアを占めました。
  • 適応症別では、腫瘍学セグメントが2024年に最大の収益シェアを占めました。この成長は、がん患者の増加によるものです。そのため、腫瘍学の臨床試験には多額の費用が費やされています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の臨床試験市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 補助市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 規制状況
  • 技術的情勢
  • 価格モデル分析
  • 臨床試験数量分析、2024年
  • 米国の臨床試験市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析
  • 段階別製品パイプライン分析
    • 開発中の治療薬
    • 開発中のワクチン

第4章 米国の臨床試験市場：フェーズの推定・動向分析

  • セグメントダッシュボード
  • 臨床試験市場：フェーズ変動分析と市場シェア、2024年と2030年
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第5章 米国の臨床試験市場：試験デザインの推定・動向分析

  • セグメントダッシュボード
  • 臨床試験市場：研究デザインの変動分析と市場シェア、2024年と2030年
  • 介入的
  • 観察的
  • 拡張アクセス

第6章 米国の臨床試験市場：適応症の推定・動向分析

  • セグメントダッシュボード
  • 臨床試験市場：適応症変動分析と市場シェア、2024年と2030年
  • 自己免疫/炎症
    • 関節リウマチ
    • 多発性硬化症
    • 変形性関節症
    • 過敏性腸症候群（IBS）
    • その他
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 腫瘍学
    • 血液がん
    • 固形腫瘍
    • その他
  • 中枢神経系の症状
    • てんかん
    • パーキンソン病（PD）
    • ハンチントン病
    • 脳卒中
    • 外傷性脳損傷（TBI）
    • 筋萎縮性側索硬化症（ALS）
    • 筋肉の再生
    • その他
  • 糖尿病
  • 肥満
  • 心臓血管
  • その他

第7章 米国の臨床試験市場：試験デザイン別、適応症別の推定・動向分析

  • セグメントダッシュボード
  • 臨床試験市場：適応症変動分析と市場シェア、2024年と2030年
  • 自己免疫/炎症
    • 介入的
    • 観察的
    • 拡張アクセス
  • 疼痛管理
    • 介入的
    • 観察的
    • 拡張アクセス
  • 腫瘍学
    • 介入的
    • 観察的
    • 拡張アクセス
  • 中枢神経系の症状
    • 介入的
    • 観察的
    • 拡張アクセス
  • 糖尿病
    • 介入的
    • 観察的
    • 拡張アクセス
  • 肥満
    • 介入的
    • 観察的
    • 拡張アクセス
  • 心臓血管
    • 介入的
    • 観察的
    • 拡張アクセス
  • その他
    • 介入的
    • 観察的
    • 拡張アクセス

第8章 米国の臨床試験市場：サービス推定・動向分析

  • セグメントダッシュボード
  • 臨床試験市場：スポンサー変動分析と市場シェア、2024年と2030年
  • プロトコル設計
  • サイトの識別
  • 患者募集
  • ラボサービス
  • バイオ分析試験サービス
  • 臨床試験データ管理サービス
  • その他

第9章 米国の臨床試験市場：スポンサーの推定・動向分析

  • セグメントダッシュボード
  • 臨床試験市場：スポンサー変動分析と市場シェア、2024年と2030年
  • 製薬・バイオ医薬品企業
  • 医療機器企業

第10章 競合情勢

  • 市場参入企業の分類
    • マーケットリーダー
    • 新興プレーヤー
  • 市況分析、2024年
  • 主要企業プロファイル
    • IQVIA
    • Fortrea Inc.
    • PAREXEL International Corporation
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories
    • ICON Plc
    • Wuxi AppTec Inc.
    • Medpace
    • Syneos Health
    • AstraZeneca
    • Merck &Co.
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Pfizer
    • Caidya
図表

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. U.S. Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 4. U.S. Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 5. U.S. Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 6. U.S. Clinical Trials Market, Indication by Study Design, 2018 - 2030 (USD Million)
  • Table 7. U.S. Clinical Trials Market, by Service, 2018 - 2030 (USD Million)
  • Table 8. U.S. Clinical Trials Market, by Sponsor, 2018 - 2030 (USD Million)
  • Table 9. Participant's Overview
  • Table 10. Financial Performance
  • Table 11. Service Benchmarking
  • Table 12. Strategic Initiatives

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Clinical Trials Market, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 PESTEL by SWOT Analysis
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 U.S. Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Clinical Trials Market, for Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Clinical Trials Market, for Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Clinical Trials Market, for Observational, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Clinical Trials Market, for Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Clinical Trials Market, for Autoimmune/Inflammation, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Clinical Trials Market, for Rheumatoid Arthritis, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Clinical Trials Market, for Multiple Sclerosis, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Clinical Trials Market, for Osteoarthritis, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Clinical Trials Market, for Irritable Bowel Syndrome (IBS), 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Clinical Trials Market, for Pain Management, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Clinical Trials Market, for Chronic Pain, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Clinical Trials Market, for Acute Pain, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Clinical Trials Market, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Clinical Trials Market, for Blood Cancer, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Clinical Trials Market, for Solid Tumors, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Clinical Trials Market, for CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Clinical Trials Market, for Epilepsy, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Clinical Trials Market, for Parkinson's Disease (PD), 2018 - 2030 (USD Million)
  • Fig. 35 U.S. Clinical Trials Market, for Huntington's Disease, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Clinical Trials Market, for Stroke, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Clinical Trials Market, for Traumatic Brain Injury (TBI), 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Clinical Trials Market, for Amyotrophic Lateral Sclerosis (ALS), 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Clinical Trials Market, for Muscle Regeneration, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Clinical Trials Market, for Diabetes, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Clinical Trials Market, for Obesity, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Clinical Trials Market, for Cardiovascular, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Clinical Trials Market, for Autoimmune/Inflammation Interventional, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. Clinical Trials Market, for Autoimmune/Inflammation Observational, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. Clinical Trials Market, for Autoimmune/Inflammation Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. Clinical Trials Market, for Pain Management Interventional, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. Clinical Trials Market, for Pain Management Observational, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. Clinical Trials Market, for Pain Management Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. Clinical Trials Market, for Oncology Interventional, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. Clinical Trials Market, for Oncology Observational, 2018 - 2030 (USD Million)
  • Fig. 53 U.S. Clinical Trials Market, for Oncology Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. Clinical Trials Market, for CNS Conditions Interventional, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. Clinical Trials Market, for CNS Conditions Observational, 2018 - 2030 (USD Million)
  • Fig. 56 U.S. Clinical Trials Market, for CNS Conditions Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 57 U.S. Clinical Trials Market, for Diabetes Interventional, 2018 - 2030 (USD Million)
  • Fig. 58 U.S. Clinical Trials Market, for Diabetes Observational, 2018 - 2030 (USD Million)
  • Fig. 59 U.S. Clinical Trials Market, for Diabetes Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 60 U.S. Clinical Trials Market, for Obesity Interventional, 2018 - 2030 (USD Million)
  • Fig. 61 U.S. Clinical Trials Market, for Obesity Observational, 2018 - 2030 (USD Million)
  • Fig. 62 U.S. Clinical Trials Market, for Obesity Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 63 U.S. Clinical Trials Market, for Cardiovascular Interventional, 2018 - 2030 (USD Million)
  • Fig. 64 U.S. Clinical Trials Market, for Cardiovascular Observational, 2018 - 2030 (USD Million)
  • Fig. 65 U.S. Clinical Trials Market, for Cardiovascular Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. Clinical Trials Market, for Other Indications Interventional, 2018 - 2030 (USD Million)
  • Fig. 67 U.S. Clinical Trials Market, for Other Indications Observational, 2018 - 2030 (USD Million)
  • Fig. 68 U.S. Clinical Trials Market, for Other Indications Expanded Access, 2018 - 2030 (USD Million)
  • Fig. 69 U.S. Clinical Trials Market, for Protocol Designing, 2018 - 2030 (USD Million)
  • Fig. 70 U.S. Clinical Trials Market, for Site Identification, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. Clinical Trials Market, for Patient Recruitment, 2018 - 2030 (USD Million)
  • Fig. 72 U.S. Clinical Trials Market, for Laboratory Services, 2018 - 2030 (USD Million)
  • Fig. 73 U.S. Clinical Trials Market, for Bioanalytical Testing Services, 2018 - 2030 (USD Million)
  • Fig. 74 U.S. Clinical Trials Market, for Clinical Trial Data Management Services, 2018 - 2030 (USD Million)
  • Fig. 75 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 76 U.S. Clinical Trials Market, for Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 77 U.S. Clinical Trials Market, for Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 78 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-580-4

U.S. Clinical Trials Market Growth & Trends:

The U.S. clinical trials market size is estimated to reach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.

The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry's growth.

The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.

U.S. Clinical Trials Market Report Highlights:

  • In 2024, the phase III dominated the market with highest revenue share. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
  • By study design, the interventional design segment dominated the U.S. market and accounted for the largest revenue share in 2024.
  • Based on indication, the oncology segment held the largest revenue share in 2024. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Regulatory Landscape
  • 3.4. Technological Landscape
  • 3.5. Pricing Model Analysis
  • 3.6. Clinical Trial Volume Analysis, 2024
  • 3.7. U.S. Clinical Trials Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL Analysis
    • 3.7.3. COVID-19 Impact Analysis
  • 3.8. Product Pipeline Analysis by Stage
    • 3.8.1. Therapeutics in Development
    • 3.8.2. Vaccines in Development

Chapter 4. U.S. Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Phase I
    • 4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Phase II
    • 4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Phase III
    • 4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Phase IV
    • 4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Interventional
    • 5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Observational
    • 5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Expanded Access
    • 5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
  • 6.3. Autoimmune/Inflammation
    • 6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Rheumatoid Arthritis
      • 6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Multiple Sclerosis
      • 6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. Osteoarthritis
      • 6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Irritable Bowel Syndrome (IBS)
      • 6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Others
      • 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Pain Management
    • 6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Chronic Pain
      • 6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Acute Pain
      • 6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Oncology
    • 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Blood Cancer
      • 6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Solid Tumors
      • 6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Others
      • 6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. CNS Conditions
    • 6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Epilepsy
      • 6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Parkinson's Disease (PD)
      • 6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Huntington's Disease
      • 6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Stroke
      • 6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Traumatic Brain Injury (TBI)
      • 6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.8. Muscle Regeneration
      • 6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.9. Others
      • 6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Diabetes
    • 6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Obesity
    • 6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.9. Cardiovascular
    • 6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
  • 7.3. Autoimmune/Inflammation
    • 7.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Interventional
      • 7.3.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Observational
      • 7.3.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Expanded Access
      • 7.3.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Pain Management
    • 7.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Interventional
      • 7.4.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Observational
      • 7.4.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Expanded Access
      • 7.4.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Interventional
      • 7.5.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Observational
      • 7.5.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. Expanded Access
      • 7.5.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. CNS Conditions
    • 7.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Interventional
      • 7.6.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Observational
      • 7.6.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Expanded Access
      • 7.6.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Diabetes
    • 7.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Interventional
      • 7.7.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Observational
      • 7.7.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. Expanded Access
      • 7.7.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Obesity
    • 7.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. Interventional
      • 7.8.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Observational
      • 7.8.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. Expanded Access
      • 7.8.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9. Cardiovascular
    • 7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.2. Interventional
      • 7.9.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.3. Observational
      • 7.9.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.9.4. Expanded Access
      • 7.9.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.2. Interventional
      • 7.10.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.3. Observational
      • 7.10.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.10.4. Expanded Access
      • 7.10.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
  • 8.3. Protocol Designing
    • 8.3.1. Protocol Designing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Site Identification
    • 8.4.1. Site Identification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Patient Recruitment
    • 8.5.1. Patient Recruitment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Laboratory Services
    • 8.6.1. Laboratory Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Bioanalytical Testing Services
    • 8.7.1. Bioanalytical Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Clinical Trial Data Management Services
    • 8.8.1. Clinical Trial Data Management Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9. Others
    • 8.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. U.S. Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
  • 9.3. Pharmaceutical & Biopharmaceutical Companies
    • 9.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Medical Device Companies
    • 9.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Position Analysis, 2024
  • 10.3. Key Company Profiles
    • 10.3.1. IQVIA
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Fortrea Inc.
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. PAREXEL International Corporation
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Thermo Fisher Scientific Inc.
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Charles River Laboratories
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. ICON Plc
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Wuxi AppTec Inc.
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Medpace
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Syneos Health
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. AstraZeneca
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Merck & Co.
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Eli Lilly and Company
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. Novo Nordisk A/S
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. Pfizer
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Caidya
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Service Benchmarking
      • 10.3.15.4. Strategic Initiatives